

FHL/SEC/2023-24

January 11, 2024

The National Stock Exchange of India Ltd.  
Scrip Symbol: FORTISBSE Limited  
Scrip Code:532843**Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).**

Dear Sir/ Ma'am,

The Company is in receipt of an email dated January 10, 2024 from National Stock Exchange India Ltd. ("NSE") along with the copy of an Administrative Warning letter bearing reference no. SEBI/HO/CFD/CFD-SEC-4/P/OW/2023/0000052377/3 dated December 27, 2023 issued by Securities and Exchange Board of India ("SEBI"). A copy of the Administrative Warning letter as received by the Company, is attached herewith as Annexure – A, in compliance with the direction of SEBI.

There is no impact on financial, operation or other activities of the Company pursuant to the above-mentioned Administrative Warning letter.

This is for your information and records.

Thanking you,  
Yours sincerely,  
For **Fortis Healthcare Limited**

  
**Murlee Manohar Jain**  
Company Secretary  
ICSI Membership: F9598



Encl. as above

03012400030



भारतीय प्रतिभूति और विनिमय बोर्ड  
Securities and Exchange Board of India

**General Manager**  
**Division of Supervision, Enforcement & Complaints – 4**  
**Corporation Finance Department**

SEBI/HO/CFD/CFD-SEC-4/P/OW/2023/0000052377/3

December 27, 2023

**FORTIS HEALTHCARE LIMITED**

Fortis Hospital,  
Sector 62, Phase - VIII,  
Mohali, Punjab – 160062.

Dear Sir/ Madam,

**Sub: Administrative Warning**

1. This is with reference to the delayed disclosure and non-disclosures of material events, timely disclosures of which were obligatory on you under the SEBI (Listing Obligations and Disclosure Requirements), 2015 ("LODR").
2. You have delayed by approximately 14 months (from the date of the *BusinessLine* report on the matter, taken into account in accordance with Annexure II to SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015 which provides guidance on when an event/ information can be said to have occurred) the disclosure of the material event of filing of a Suit in a US Court seeking USD 6.5 billion in damages. This was in violation of Regulations 4(1)(d) and (e) and Regulation 30(6) read with Regulations 30(3) and 30(4)(i)(b) and Clause 8 of Para B of Part A of Schedule III of the LODR.
3. You have also failed to disclose the Interim Award dated October 17, 2022 in the arbitration proceedings titled 'Balaji Great Lotus Glory vs Eleos Finvestia Acquisition Trust & Ors.' and the subsequent material developments in the matter regarding the filing of a Suit before the Hon'ble High Court of Delhi and the termination of the Interim Award vide order dated January 11, 2023. This was in violation of Regulations 4(1)(d) and (e) and Regulations 30(3) and 30(7) read with Regulations 30(4)(i)(a) and (b) and Clause 8 of Para B of Part A of Schedule III of the LODR.
4. The above violations have been viewed seriously. You are therefore warned to be careful in future and are advised to exercise due caution in future and avoid recurrence of such instances failing which appropriate enforcement action may be initiated in accordance with the provisions of SEBI Act, 1992 and the Rules and Regulations framed thereunder.
5. You are also advised to take corrective steps, place this communication and the corrective steps taken before the Board of Directors and disseminate a copy of this communication on the websites of the Exchanges that you are listed on.

Yours faithfully,

**Dipanjan Mitra**

**Copy to: (1) BSE Ltd.**  
**(2) National Stock Exchange of India Ltd.**